Paris—Dentons Paris advised Bpifrance Large Venture on the Series A funding of Aqemia.
Aqemia is a Paris-based deeptech founded in 2019 and specialised in drug discovery by combining quantum physics and artificial intelligence.
The €30 million Series A funding round was co-led by Eurazeo and Bpifrance, through its Large Venture fund, with the participation of Elaia, its historic investor.
This financing will further support Aqemia's core mission: to massively advance drug discovery through a first-class technology platform combining quantum-inspired physics and artificial intelligence.
Our multidisciplinary Paris team included:
Redefining possibilities. Together, everywhere. For more information visit dentons.com